Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer.
Zatloukal P, Gervais R, Vansteenkiste J, Bosquee L, Sessa C, Brain E, Dansin E, Urban T, Dohollou N, Besenval M, Quoix E. Zatloukal P, et al. Among authors: bosquee l. J Thorac Oncol. 2008 Aug;3(8):894-901. doi: 10.1097/JTO.0b013e31817e6669. J Thorac Oncol. 2008. PMID: 18670308 Free article. Clinical Trial.
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Scagliotti GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R, Planchard D, Reck M, De Marinis F, Lee JS, Park K, Biesma B, Gans S, Ramlau R, Szczesna A, Makhson A, Manikhas G, Morgan B, Zhu Y, Chan KC, von Pawel J. Scagliotti GV, et al. Among authors: bosquee l. Lung Cancer. 2010 Jun;68(3):420-6. doi: 10.1016/j.lungcan.2009.07.011. Epub 2009 Aug 18. Lung Cancer. 2010. PMID: 19692142 Clinical Trial.
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, Huitema AD, Norbury CJ, Ellis P, Bosquee L, Reck M. Talbot DC, et al. Among authors: bosquee l. Clin Cancer Res. 2007 Mar 15;13(6):1816-22. doi: 10.1158/1078-0432.CCR-06-0249. Clin Cancer Res. 2007. PMID: 17363538 Free article. Clinical Trial.
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
van Puijenbroek R, Bosquée L, Meert AP, Schallier D, Goeminne JC, Tits G, Collard P, Nackaerts K, Canon JL, Duplaquet F, Galdermans D, Germonpré P, Azerad MA, Vandenhoven G, De Greve J, Vansteenkiste J. van Puijenbroek R, et al. Among authors: bosquee l. Eur Respir J. 2007 Jan;29(1):128-33. doi: 10.1183/09031936.00050706. Epub 2006 Sep 27. Eur Respir J. 2007. PMID: 17005582 Free article.
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF. von Pawel J, et al. Among authors: bosquee l. J Clin Oncol. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10. J Clin Oncol. 2014. PMID: 25385727 Clinical Trial.
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y, Bosquée L, Pasini F, Marangolo M. Leyvraz S, et al. Among authors: bosquee l. J Clin Oncol. 1999 Nov;17(11):3531-9. doi: 10.1200/JCO.1999.17.11.3531. J Clin Oncol. 1999. PMID: 10550151 Clinical Trial.
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clinique de l'Université Catholique de Louvain, Brussels and Liège, Belgium.
van de Velde H, Bosquée L, Weynants P, Canon JL, Rosier JF, Humblet Y. van de Velde H, et al. Among authors: bosquee l. Ann Oncol. 1999 Sep;10(9):1051-7. doi: 10.1023/a:1008306732232. Ann Oncol. 1999. PMID: 10572602 Free article. Clinical Trial.
48 results